Multiple studies have demonstrated that IL-6-mediated EMP and stemness provide resistance to conventional chemo(radio)therapy in different cancer types [59,88,90,136] and even to targeted therapy, such as trastuzumab [77] or tyrosine kinase inhibitors (TKIs) [137,138]. This evidence concerns the gene IL6 and cancer.